Chemotherapeutic Strategies for Reducing Transmission of Plasmodium vivax Malaria - Advances in Parasitology - page 296

Macauley, C., 2005. Aggressive active case detection: a malaria control strategy based on the
Brazilian model. Soc. Sci. Med. 60 (3), 563-573.
Maneeboonyang, W., et al., 2011. Directly observed therapy with primaquine to reduce the
recurrence rate of Plasmodium vivax infection along the Thai-Myanmar border. South-
east Asian J. Trop. Med. Public Health 42 (1), 9-18.
Mayxay, M., et al., 2004. Randomized comparison of chloroquine plus sulfadoxine-pyri-
methamine versus artesunate plus mefloquine versus artemether-lumefantrine in the
treatment of uncomplicated falciparum malaria in the Lao People's Democratic Repub-
lic. Clin. Infect. Dis. 39 (8), 1139-1147.
McGready, R., et al., 2008. A randomised controlled trial of artemether-lumefantrine versus
artesunate for uncomplicated Plasmodium falciparum treatment in pregnancy. PLoS Med.
5 (12), e253.
Medicines for Malaria Venture, 2011. Interactive Science Portfolio. (cited 2012 11th of
March 2012); Available from: http://www.mmv.org/research-development/science-
portfolio .
Michon, P., et al., 2007. The risk of malarial infections and disease in Papua New Guinean
children. Am. J. Trop. Med. Hyg. 76 (6), 997-1008.
Miller, L.H., et al., 1974. Sensitivity of four Central American strains of Plasmodium vivax to
primaquine. Am. J. Trop. Med. Hyg. 23 (2), 309-310.
Mueller, I., et al., 2009. Key gaps in the knowledge of Plasmodium vivax , a neglected human
malaria parasite. Lancet Infect. Dis. 9 (9), 555-566.
Nkhoma, E.T., et al., 2009. The global prevalence of glucose-6-phosphate dehydroge-
nase deficiency: a systematic review and meta-analysis. Blood Cells Mol. Dis. 42 (3),
267-278.
Nosten, F., et al., 2000. Effects of artesunate-mefloquine combination on incidence of Plas-
modium falciparum malaria and mefloquine resistance in Western Thailand: a prospective
study. Lancet 356 (9226), 297-302.
Onori, E., 1972. Experience with mass drug administration as a supplementary attack mea-
sure in areas of vivax malaria. Bull. World Health Organ. 47 (5), 543-548.
Phimpraphi, W., et al., 2008. Longitudinal study of Plasmodium falciparum and Plasmodium
vivax in a Karen population in Thailand. Malar. J. 7 (1), 99.
Phyo, A.P., et al., 2011. Dihydroartemisinin-piperaquine versus chloroquine in the treat-
ment of P. vivax malaria in Thailand: a randomized controlled trial. Clin. Infect. Dis. 53,
977-984.
Poespoprodjo, J.R., et al., 2009. Vivax malaria: a major cause of morbidity in early infancy.
Clin. Infect. Dis. 48 (12), 1704-1712.
Poravuth, Y., et al., 2011. Pyronaridine-artesunate versus chloroquine in patients with acute
Plasmodium vivax malaria: a randomized, double-blind, non-inferiority trial. PLoS One
6 (1), e14501.
Poschl, B., et al., 2010. Comparative diagnosis of malaria infections by microscopy, nested
PCR, and LAMP in Northern Thailand. Am. J. Trop. Med. Hyg. 83 (1), 56-60.
Price, R.N., Douglas, N.M., 2010. Maximising the public health benefit of antimalarials.
Lancet Infect. Dis. 10 (10), 654-655.
Price, R.N., et al., 2007. Vivax malaria: neglected and not benign. Am. J. Trop. Med. Hyg.
77, 79-87.
Pukrittayakamee, S., et al., 2004. Therapeutic responses to antimalarial and antibacterial
drugs in vivax malaria. Acta Trop. 89, 351-356.
Pukrittayakamee, S., et al., 2008. Effects of different antimalarial drugs on gametocyte car-
riage in P. vivax malaria. Am. J. Trop. Med. Hyg. 79 (3), 378-384.
Pukrittayakamee, S., et al., 2010. A comparison of two short-course primaquine regimens
for the treatment and radical cure of Plasmodium vivax malaria in Thailand. Am. J. Trop.
Med. Hyg. 82 (4), 542-547.